🇺🇸 FDA
Patent

US 12351561

Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

granted A61KA61K31/415A61K45/06

Quick answer

US patent 12351561 (Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof) held by Theravance Biopharma R&D IP, LLC expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
63
CPC classes
A61K, A61K31/415, A61K45/06, A61K9/0053, A61K9/4816